A LinkedIn post from Parallel Fluidics highlights on-site demonstrations of its LNP Screening Array for local biopharma customers in the Boston area. The post indicates the company is willing to deploy its system directly onto prospective customers’ existing liquid handlers and run live demonstrations with their teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post further suggests Parallel Fluidics is offering “Starter Arrays” that allow labs to run initial lipid nanoparticle campaigns at no additional cost. For investors, this hands-on, low-friction trial model may help accelerate adoption of the firm’s microfluidics-based lab automation tools, deepen relationships with Boston’s concentrated biopharma ecosystem, and potentially expand recurring revenue opportunities if pilots convert into broader deployments.